FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075425755> ?p ?o ?g. }

• W2075425755 endingPage "961" @default.
• W2075425755 startingPage "952" @default.
• W2075425755 abstract "Objective: To investigate community-acquired pneumonia (CAP) as a cause of severe sepsis in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial and to evaluate the effect of drotrecogin alfa (activated) (DrotAA) in this subgroup. Design: Retrospective analysis of the severe CAP subgroup in the PROWESS trial. Setting: Tertiary care institutions in 11 countries. Interventions: DrotAA (n = 850), 24 μg·kg−1·hr−1 for 96 hrs, or placebo (n = 840). Participants: The 1,690 patients with severe sepsis enrolled in the PROWESS trial. Measurements and Main Results: Patients were classified as having CAP if lung was the primary site of infection and if they were enrolled directly from home (private residence) with ≤4 days in the hospital before receipt of study drug in the PROWESS trial. Survival at 28 days, hospital discharge, and 90 days was compared in DrotAA and placebo groups in the CAP subgroup of PROWESS and CAP subgroups based on disease severity. Of the 1,690 PROWESS patients, 35.6% (DrotAA, n = 324; placebo, n = 278) were classified as severe CAP. Of these severe CAP patients, 26.1% had Streptococcus pneumoniae infections. Within CAP, 79.1% were enrolled by the end of the second calendar day in the hospital, and approximately 90% of CAP patients were at high risk of death according to the Pneumonia Severity Index category. Based on their dependence on vasopressors, 59% of CAP patients were judged at high risk of death. Biomarkers of coagulation and inflammation were markedly abnormal in severe CAP patients. In severe CAP patients treated with DrotAA, a relative risk reduction in mortality of 28% was observed at 28 days, with a relative risk reduction in mortality of 14% observed at 90 days from the start of study drug infusion. The survival benefit was most pronounced in severe CAP patients with S. pneumoniae and in severe CAP patients at high risk of death as indicated by Acute Physiology and Chronic Health Evaluation II score of ≥25, Pneumonia Severity Index score of ≥4, or CURB-65 (confusion, urea, respiratory rate, blood pressure, age) score of ≥3. Conclusions: CAP associated with a high Pneumonia Severity Index score, bacteremia, or an intense coagulation and inflammatory response requiring intensive care unit care were indicators of a high risk of death from severe sepsis. In patients with severe sepsis resulting from CAP, a readily identifiable disease, DrotAA, improved survival compared with placebo." @default.
• W2075425755 created "2016-06-24" @default.
• W2075425755 creator A5003902575 @default.
• W2075425755 creator A5031614362 @default.
• W2075425755 creator A5037398399 @default.
• W2075425755 creator A5037790279 @default.
• W2075425755 creator A5042697024 @default.
• W2075425755 creator A5045591705 @default.
• W2075425755 creator A5050393463 @default.
• W2075425755 creator A5059311893 @default.
• W2075425755 creator A5063505202 @default.
• W2075425755 creator A5079184641 @default.
• W2075425755 date "2005-05-01" @default.
• W2075425755 modified "2023-10-16" @default.
• W2075425755 title "Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*" @default.
• W2075425755 cites W1525697383 @default.
• W2075425755 cites W1898928487 @default.
• W2075425755 cites W1980983465 @default.
• W2075425755 cites W2003549927 @default.
• W2075425755 cites W2012545798 @default.
• W2075425755 cites W2012906489 @default.
• W2075425755 cites W2045932891 @default.
• W2075425755 cites W2049927822 @default.
• W2075425755 cites W2056292711 @default.
• W2075425755 cites W2070946600 @default.
• W2075425755 cites W2092993771 @default.
• W2075425755 cites W2093648826 @default.
• W2075425755 cites W2102361557 @default.
• W2075425755 cites W2106228247 @default.
• W2075425755 cites W2112302527 @default.
• W2075425755 cites W2112722942 @default.
• W2075425755 cites W2117196810 @default.
• W2075425755 cites W2121756063 @default.
• W2075425755 cites W2130141864 @default.
• W2075425755 cites W2142230428 @default.
• W2075425755 cites W2144283370 @default.
• W2075425755 cites W2147581820 @default.
• W2075425755 cites W2169493333 @default.
• W2075425755 cites W2320270386 @default.
• W2075425755 cites W2322121630 @default.
• W2075425755 cites W2328201454 @default.
• W2075425755 cites W4293241248 @default.
• W2075425755 cites W4293242440 @default.
• W2075425755 doi "https://doi.org/10.1097/01.ccm.0000162381.24074.d7" @default.
• W2075425755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15891319" @default.
• W2075425755 hasPublicationYear "2005" @default.
• W2075425755 type Work @default.
• W2075425755 sameAs 2075425755 @default.
• W2075425755 citedByCount "186" @default.
• W2075425755 countsByYear W20754257552012 @default.
• W2075425755 countsByYear W20754257552013 @default.
• W2075425755 countsByYear W20754257552014 @default.
• W2075425755 countsByYear W20754257552015 @default.
• W2075425755 countsByYear W20754257552016 @default.
• W2075425755 countsByYear W20754257552017 @default.
• W2075425755 countsByYear W20754257552018 @default.
• W2075425755 countsByYear W20754257552020 @default.
• W2075425755 countsByYear W20754257552021 @default.
• W2075425755 countsByYear W20754257552023 @default.
• W2075425755 crossrefType "journal-article" @default.
• W2075425755 hasAuthorship W2075425755A5003902575 @default.
• W2075425755 hasAuthorship W2075425755A5031614362 @default.
• W2075425755 hasAuthorship W2075425755A5037398399 @default.
• W2075425755 hasAuthorship W2075425755A5037790279 @default.
• W2075425755 hasAuthorship W2075425755A5042697024 @default.
• W2075425755 hasAuthorship W2075425755A5045591705 @default.
• W2075425755 hasAuthorship W2075425755A5050393463 @default.
• W2075425755 hasAuthorship W2075425755A5059311893 @default.
• W2075425755 hasAuthorship W2075425755A5063505202 @default.
• W2075425755 hasAuthorship W2075425755A5079184641 @default.
• W2075425755 hasConcept C126322002 @default.
• W2075425755 hasConcept C141071460 @default.
• W2075425755 hasConcept C142724271 @default.
• W2075425755 hasConcept C204787440 @default.
• W2075425755 hasConcept C27081682 @default.
• W2075425755 hasConcept C2776102371 @default.
• W2075425755 hasConcept C2777628635 @default.
• W2075425755 hasConcept C2777914695 @default.
• W2075425755 hasConcept C2778005785 @default.
• W2075425755 hasConcept C2778314733 @default.
• W2075425755 hasConcept C2778384902 @default.
• W2075425755 hasConcept C2994086866 @default.
• W2075425755 hasConcept C71924100 @default.
• W2075425755 hasConceptScore W2075425755C126322002 @default.
• W2075425755 hasConceptScore W2075425755C141071460 @default.
• W2075425755 hasConceptScore W2075425755C142724271 @default.
• W2075425755 hasConceptScore W2075425755C204787440 @default.
• W2075425755 hasConceptScore W2075425755C27081682 @default.
• W2075425755 hasConceptScore W2075425755C2776102371 @default.
• W2075425755 hasConceptScore W2075425755C2777628635 @default.
• W2075425755 hasConceptScore W2075425755C2777914695 @default.
• W2075425755 hasConceptScore W2075425755C2778005785 @default.
• W2075425755 hasConceptScore W2075425755C2778314733 @default.
• W2075425755 hasConceptScore W2075425755C2778384902 @default.
• W2075425755 hasConceptScore W2075425755C2994086866 @default.
• W2075425755 hasConceptScore W2075425755C71924100 @default.
• W2075425755 hasIssue "5" @default.
• W2075425755 hasLocation W20754257551 @default.

• next